跳至主要内容
临床试验/NCT06734468
NCT06734468进行中(未招募)不适用

Personalized Approach to Promote Healthy Aging

Arizona State University3 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2024年10月7日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
25
试验地点
3
主要终点
VO2 max

研究概览

简要总结

The goal of this clinical trial study is to evaluate the impact of a personalized lifestyle intervention on improving healthspan. The primary questions of interest are whether the personalized intervention will result in improvements in muscle function, immune function, and cognitive function in adults aged 50-85 years. Participants will complete baseline assessments, receive an individualized intervention plan for approximately 3 months, and then complete post-intervention assessments. The intervention includes an exercise plan, nutrition recommendations, and general lifestyle goals that will be personalized to each participant.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
50 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 50-85 years of age
  • Non-smoking
  • Ambulatory without the need of an assistive device (walker, cane, etc.) and able to perform exercise testing and exercise training
  • English speaking
  • Owns a smart phone

排除标准

  • Minors and adults younger than age 50 years and older than 85 years
  • Pregnant women
  • Adults who are unable to provide informed consent
  • Prisoners

研究组 & 干预措施

Lifestyle Intervention

Experimental

All participants will receive an intervention.

干预措施: Lifestyle Management (Behavioral)

结局指标

主要结局

VO2 max

时间窗: From baseline to the end of the intervention at 3 months.

A maximal treadmill exercise test with respiratory gas exchange analysis to assess cardiorespiratory fitness.

Biodex

时间窗: From baseline to the end of the intervention at 3 months.

A Biodex will be used to assess leg muscle power and strength.

次要结局

  • World Health Organization Quality of Life Survey(From baseline to the end of the intervention at 3 months.)
  • Pittsburgh Sleep Quality Index(From baseline to the end of the intervention at 3 months.)
  • Handgrip strength(From baseline to the end of the intervention at 3 months.)
  • Dual Energy X-ray Absorptiometry (DXA)(From baseline to the end of the intervention at 3 months.)
  • Waist circumference(From baseline to the end of the intervention at 3 months.)
  • Hip circumference(From baseline to the end of the intervention at 3 months.)
  • Systolic blood pressure(From baseline to the end of the intervention at 3 months.)
  • Diastolic blood pressure(From baseline to the end of the intervention at 3 months.)
  • Digit Symbol Substitution Test (DSST)(From baseline to the end of the intervention at 3 months.)
  • Montreal Cognitive Assessment (MoCA)(From baseline to the end of the intervention at 3 months.)
  • Short Physical Performance Battery(From baseline to the end of the intervention at 3 months.)
  • Low Density Lipoprotein Cholesterol(From baseline to the end of the intervention at 3 months.)
  • Hemoglobin A1C Concentration(From baseline to the end of the intervention at 3 months.)
  • Insulin Concentration(From baseline to the end of the intervention at 3 months.)
  • Geriatric Depression Scale (GDS)(From baseline to the end of the intervention at 3 months.)
  • Generalized Anxiety Disorder (GAD)-7(From baseline to the end of the intervention at 3 months.)
  • Perceived Stress Scale(From baseline to the end of the intervention at 3 months.)
  • High Density Lipoprotein Cholesterol(From baseline to the end of the intervention at 3 months.)
  • Brief Resilience Scale(From baseline to the end of the intervention at 3 months.)
  • Non-High Density Lipoprotein Cholesterol(From baseline to the end of the intervention at 3 months.)
  • Very Low Density Lipoprotein Cholesterol(From baseline to the end of the intervention at 3 months.)
  • CD3 T cells(From baseline to the end of the intervention at 3 months.)
  • CD4 T cells(From baseline to the end of the intervention at 3 months.)
  • CD8 T cells(From baseline to the end of the intervention at 3 months.)
  • Natural Killer cells(From baseline to the end of the intervention at 3 months.)
  • B cells(From baseline to the end of the intervention at 3 months.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Susan Racette

Professor

Arizona State University

研究点 (3)

Loading locations...

相似试验